REGISTERED
on 29 Nov 2022
Last Applicant/ Owned by
Connaught House, 1 Burlington Road
Dublin 4
IE
Serial Number
88489837 filed on 26th Jun 2019
Registration Number
6913410 registered on 29th Nov 2022
Filing Basis
1. intent to use
2. use application currently
Disclaimer
NO DATA
LYBALVI
Pharmaceutical preparations for the treatment of psychiatric and neurodegenerative diseases and disorders including schizophrenia, depression, major depressive disorder, stress, anxiety, treatment resistant depression, bipolar depression, bipolar disorder; pharmaceutical preparations for the mitigation of weight gain and the treatment of metabolic diseases and dyslipidemia
Classification Information
Class [005]
Pharmaceutical Products
Pharmaceutical preparations for the treatment of psychiatric and neurodegenerative diseases and disorders including schizophrenia, depression, major depressive disorder, stress, anxiety, treatment resistant depression, bipolar depression, bipolar disorder; pharmaceutical preparations for the mitigation of weight gain and the treatment of metabolic diseases and dyslipidemia
First Use Date in General
11th Oct 2021
First Use Date in Commerce
15th Oct 2021
Specimens
Mark Details
Serial Number
No 88489837
Mark Type
No Service/Collective Mark
Attorney Docket Number
No 029318-2810
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Design Code(s)
24.07.07 -
Prize ribbons
Legal History
| Status Date | Action Taken |
|---|---|
| 29th Nov 2022 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| 29th Nov 2022 | REGISTERED-PRINCIPAL REGISTER |
| 28th Oct 2022 | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| 27th Oct 2022 | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| 17th Oct 2022 | ASSIGNED TO EXAMINER |
| 04th Oct 2022 | STATEMENT OF USE PROCESSING COMPLETE |
| 07th Jan 2022 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| 06th Jan 2022 | SOU EXTENSION 4 GRANTED |
| 28th Dec 2021 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| 17th Dec 2021 | USE AMENDMENT FILED |